Fiche publication
Date publication
mai 2024
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
,
Dr LADOIRE Sylvain
Tous les auteurs :
Baboudjian M, Peyrottes A, Dariane C, Fromont G, Denis JA, Fiard G, Kassab D, Ladoire S, Lehmann-Che J, Ploussard G, Rouprêt M, Barthélémy P, Roubaud G, Lamy PJ
Lien Pubmed
Résumé
Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa. Current research focuses on the description and validation of novel predictive biomarkers to improve precision medicine in mPCa. Our aim was to systematically review the current evidence on liquid biopsy biomarkers for predicting treatment response in mPCa.
Mots clés
Androgen receptor, Circulating biomarkers, Circulating tumor cells, DNA damage repair, Homologous recombination repair, Liquid biopsy, Metastatic prostate cancer, PARP inhibitor, Treatment prediction
Référence
Eur Urol Oncol. 2024 05 31;:
